Moderna Stock News

Moderna on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between 2026 and 2028.

Moderna Inc. on Thursday touted progress toward new vaccine approvals but said it will rein in its research and development spending and trim its pipeline as it looks to shake off the doldrums of a dwindling COVID vaccine market.

Covid vaccine maker Moderna plans to sextuple the number of products it has approved over the next three years, the company said Thursday.

Moderna said it plans to cut $1.1 billion in expenses by 2027 as it charts a path forward after the rapid decline of its Covid business.  The biotech company said it expects 10 new product approvals through 2027.

Focuses on ten product approvals through 2027 Expects to submit next-generation COVID vaccine for approval in 2024 Expects to submit flu/COVID combination vaccine for approval in 2024 Announces positive Phase 3 results for its RSV vaccine for high-risk adults aged 18 to 59; expects to submit sBLA for U.S. approval in 2024 Announces positive Phase 3 results for its standalone flu vaccine for adu...

NEW YORK , Sept. 12, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Moderna, Inc. (NASDAQ: MRNA).

These companies are innovators and either already have at least one commercialized product or are close to the finish line. One of these players has climbed this year, while the other two have declined -- but they each offer solid long-term share performance potential.

Die Aktien des Impfstoffherstellers Moderna US60770K1079 sind am Donnerstag nach einem mit Enttäuschung aufgenommenen Umsatzausblick auf den tiefsten Stand seit November 2023 gesackt.